Journal
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
Volume 15, Issue -, Pages -Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/17588359231152839
Keywords
prostate cancer; lipids; targeted therapy; high-fat diet
Categories
Ask authors/readers for more resources
This article summarizes the epidemiological links between obesity and metabolic syndrome and prostate cancer, the evidence for altered circulating lipids in prostate cancer and their potential role as biomarkers, as well as novel therapeutic strategies for targeting lipids in men with prostate cancer.
Despite key advances in the treatment of prostate cancer (PCa), a proportion of men have de novo resistance, and all will develop resistance to current therapeutics over time. Aberrant lipid metabolism has long been associated with prostate carcinogenesis and progression, but more recently there has been an explosion of preclinical and clinical data which is informing new clinical trials. This review explores the epidemiological links between obesity and metabolic syndrome and PCa, the evidence for altered circulating lipids in PCa and their potential role as biomarkers, as well as novel therapeutic strategies for targeting lipids in men with PCa, including therapies widely used in cardiovascular disease such as statins, metformin and lifestyle modification, as well as novel targeted agents such as sphingosine kinase inhibitors, DES1 inhibitors and agents targeting FASN and beta oxidation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available